Rabbit antithymocyte globulin dose does not affect response or survival as first-line therapy for acquired aplastic anemia: a multicenter retrospective study

In a prospective randomized study, treatment for aplastic anemia (AA) with rabbit antithymocyte globulin (r-ATG) and cyclosporine showed inferior hematological response and survival in comparison to horse antithymocyte globulin (h-ATG) and cyclosporine. However, h-ATG was discontinued in most Asian,...

Full description

Saved in:
Bibliographic Details
Published in:Annals of hematology 2018-11, Vol.97 (11), p.2039-2046
Main Authors: Clé, Diego V., Atta, Elias H., Dias, Danielle S. P., Lima, Carlos B. L., Bonduel, Mariana, Sciuccati, Gabriela, Medeiros, Larissa A., de Oliveira, Michel M., Blum Fonseca, Patricia B., Saad, Sara T. O., Hamerschlak, Nelson, Salvino, Marco A., Garanito, Marlene P., Pazin-Filho, Antonio, Scheinberg, Phillip, Calado, Rodrigo T.
Format: Article
Language:English
Subjects:
Anemia
Hematology
Medicine
Medicine & Public Health
Oncology
Original Article
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In a prospective randomized study, treatment for aplastic anemia (AA) with rabbit antithymocyte globulin (r-ATG) and cyclosporine showed inferior hematological response and survival in comparison to horse antithymocyte globulin (h-ATG) and cyclosporine. However, h-ATG was discontinued in most Asian, South American, and European countries, where r-ATG became the only ATG formulation available. We retrospectively evaluated consecutive patients with acquired AA who received either rabbit ( n  = 170) or horse ( n  = 85) ATG and cyclosporine for first-line treatment from 1992 to 2014 in seven referral centers in Brazil and Argentina. Overall response at 3 months was 17% (95%CI, 11–23%) for r-ATG and 44% (95%CI, 33–55%) for h-ATG ( p  
ISSN:0939-5555
1432-0584
DOI:10.1007/s00277-018-3416-4